Apollomics (APLM)
NASDAQ:APLM
Top Page
Apollomics
(NASDAQ:APLM)
Select Model
Select Model
Rating:52Neutral
Price Target:
$18.00
▼(-20.07% Downside)
Action:ReiteratedDate:12/27/25
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and negative cash flow). This is partially offset by strong technicals (price above key moving averages with positive MACD and healthy RSI), while valuation remains constrained due to negative earnings and no dividend support.
Positive Factors
Focused oncology pipeline
A clear, clinical-stage oncology focus concentrates R&D resources and expertise, improving trial prioritization and partner visibility. Structural focus increases the chance that successful trial readouts produce lasting value and strategic partnerships over the next 2–6 months.
Negative Factors
Persistent negative operating and free cash flows
Ongoing negative operating and free cash flows erode liquidity and force reliance on dilutive financings or partnership deals to fund trials. Over months this constraint can delay programs, dilute shareholders, and limit strategic optionality if not resolved.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused oncology pipeline
A clear, clinical-stage oncology focus concentrates R&D resources and expertise, improving trial prioritization and partner visibility. Structural focus increases the chance that successful trial readouts produce lasting value and strategic partnerships over the next 2–6 months.
Read all positive factors
Apollomics (APLM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.99M
Dividend YieldN/A
Average Volume (3M)72.65K
Price to Earnings (P/E)―
Beta (1Y)0.61
Revenue GrowthN/A
EPS Growth54.41%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,103,348
10 Day Avg. Volume95,090
30 Day Avg. Volume72,653
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.86
Price to Sales (P/S)45.62
P/FCF Ratio-0.31
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue79.01
Enterprise Value/Gross Profit79.01
Enterprise Value/Ebitda-0.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-122
Revenue Forecast (FY)N/A
Apollomics Business Overview & Revenue Model
Company Description
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selectiv...
How the Company Makes Money
Apollomics generates revenue through several key streams, including partnerships with pharmaceutical companies for co-development agreements and licensing deals for its drug candidates. The company may also receive milestone payments as its produc...
Apollomics Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
25
Negative
Cash Flow
20
Very Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 198.00K | 821.00K | 323.00K | 2.00K | 1.84M |
| Gross Profit | 198.00K | 821.00K | 323.00K | 2.00K | 1.84M |
| EBITDA | -41.05M | -53.45M | -43.88M | -50.12M | -40.51M |
| Net Income | -53.86M | -172.60M | -240.81M | -94.80M | -74.82M |
Balance Sheet | |||||
| Total Assets | 13.10M | 55.39M | 76.47M | 123.44M | 169.94M |
| Cash, Cash Equivalents and Short-Term Investments | 9.77M | 37.82M | 54.61M | 94.48M | 154.39M |
| Total Debt | 966.00K | 4.66M | 991.00K | 325.41M | 289.55M |
| Total Liabilities | 8.23M | 14.15M | 524.60M | 336.30M | 297.87M |
| Stockholders Equity | 4.86M | 41.23M | -448.12M | -212.86M | -127.93M |
Cash Flow | |||||
| Free Cash Flow | -28.77M | -43.22M | -43.19M | -43.36M | -35.82M |
| Operating Cash Flow | -28.74M | -43.21M | -42.82M | -43.31M | -35.68M |
| Investing Cash Flow | 5.98M | 21.36M | 29.05M | -38.95M | 2.33M |
| Financing Cash Flow | 468.00K | 21.23M | -294.00K | -1.64M | 125.51M |
Apollomics Technical Analysis
Negative
22.52
Price Trends
18.86
Negative
18.49
Negative
14.94
Positive
Market Momentum
-1.33
Positive
34.93
Neutral
15.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLM, the sentiment is Negative. The current price of 22.52 is above the 20-day moving average (MA) of 17.49, above the 50-day MA of 18.86, and above the 200-day MA of 14.94, indicating a neutral trend. The MACD of -1.33 indicates Positive momentum. The RSI at 34.93 is Neutral, neither overbought nor oversold. The STOCH value of 15.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APLM.
Apollomics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $16.99M | -0.14 | -380.13% | ― | ― | 54.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $11.83M | -7.53 | -42.29% | ― | ― | -21.99% | |
43 Neutral | $14.95M | -0.72 | -364.96% | ― | -48.74% | 89.18% | |
43 Neutral | $25.69M | -6.90 | -108.76% | ― | -100.00% | 33.44% | |
41 Neutral | $4.89M | -1.49 | -92.74% | ― | 280.77% | 32.82% |
* Healthcare Sector Average
APLM
Apollomics
15.40
9.72
171.13%
HIND
Vyome Holdings
2.13
-32.09
-93.78%
CLGN
Collplant Holdings
0.34
-2.16
-86.44%
LNAI
Lunai Bioworks
0.36
-3.79
-91.39%
XCUR
Exicure
4.03
-7.47
-64.96%
GDTC
CytoMed Therapeutics Limited
1.00
-1.74
-63.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.